In conclusion, based on results of our GSEA analysis and knowledge from clinical trials we suggest the highest potential of alisertib and mesupron for CDK2 and PLAU-targeted therapy of lymph node negative luminal A breast cancer patients with high risk of distant metastasis. Here, PLAU is linked to benign neoplasm.